

Review began 11/15/2023

Review ended 12/04/2023

Published 12/08/2023

© Copyright 2023

Kumar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

# Gallium68-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT as an Alternative to Fluoro18-Fluorodeoxyglucose (18F-FDG) PET/CT: Discussion in a Case of Metastatic Adenocarcinoma of Pancreas

Abhishek Kumar <sup>1</sup>, Bhola Kumar <sup>1</sup>, Amitabh Kumar Upadhyay <sup>2</sup>, G. S. Muthu <sup>3</sup>, Sujata Mitra <sup>1</sup>

1. Nuclear Medicine, Tata Main Hospital, Jamshedpur, IND 2. Medical Oncology, Tata Main Hospital, Jamshedpur, IND 3. Nuclear Medicine, Meherbai Tata Memorial Hospital, Jamshedpur, IND

Corresponding author: Abhishek Kumar, mymail.abhishek@gmail.com

## Abstract

Positron emission tomography (PET) is an integral part of the imaging of solid tumors in today's oncology practice. The most commonly used PET radiotracer is 18F-Fluorodeoxyglucose (18F-FDG). FDG PET has imaging characteristics of a high tumor-to-background uptake ratio and is used in the detection of primary as well as metastatic sites. However, a significant pitfall is its inability to differentiate between neoplastic and infective lesions. To address this concern, many PET radiotracers have been developed and tried over time, a promising one being radiolabelled fibroblast activation protein inhibitor (FAPI). Fibroblast-activated protein (FAP) is a type II transmembrane glycoprotein expressed by cancer-associated fibroblasts (CAFs); it forms a significant component of the tumor stroma. Since there is over-expression of CAF in the majority of malignancies, it is a potential target for molecular imaging using PET. Several radiolabeled FAP inhibitors have been developed for PET imaging of malignancies and have also been used in theranostic applications.

**Categories:** Radiology, Oncology, Nuclear Medicine

**Keywords:** fibroblast activation protein inhibitor, 68ga - fapi, 18f - fdg, pet/ct, 18f-fluorodeoxyglucose-positron emission tomography, positron emission tomography, 18f-fluorodeoxyglucose

## Introduction

Molecular imaging has revolutionized the field of imaging. The hybrid imaging modality positron emission tomography/computed tomography (PET/CT) not only gives details on morphology and anatomy but also visualizes the physiological and pathological processes within the organs and lesions at the cellular level. 18F-Fluorodeoxyglucose (18F-FDG) is one of the most widely used PET/CT radiotracers [1]. It is not only used in oncology but also used to detect infective and inflammatory etiology. It also serves as a radiotracer to determine the viability of the left ventricle myocardium in the field of cardiology. Other commonly used PET radiotracers are 68Ga-DOTANOC in cases of neuroendocrine tumors and 68Ga/18F-PSMA in cases of adenocarcinoma prostate [2-5]. These 68Ga radiolabeled PET radiotracers are synthesized at the PET/CT facility from 68Ge/68Ga generators. These portable generators offer the advantage of radiotracer availability at PET/CT centers distant from medical cyclotrons. Unlike in the case of 18F-FDG, these 68Ga-based radiotracers are not dependent on the blood glucose levels of the patient and offer another advantage in performing PET/CT independent of blood glucose levels. The 18F-FDG uptake is dependent on the blood glucose levels of patients and poses a challenge in cases of diabetics, wherein the patient has to be fasting for at least four hours [6]. The time gap between antidiabetic medications and 18F-FDG PET/CT must also be managed so that these medications do not interfere with FDG uptake.

Moreover, FDG uptake is a surrogate for glucose transport/metabolism and is not specific for malignancy [7,8]. There has always been research to develop more specific radiotracers for malignancy. The radiolabeled somatostatin receptor (SSTR) targeting agents and prostate-specific membrane antigen (PSMA) ligands result from translational research. The search for cellular targets led to the discovery of fibroblast activation protein, a transmembrane glycoprotein expressed on activated fibroblasts such as cancer-associated fibroblasts (CAFs) [9]. The new PET radiotracer 68-FAPI targets these CAFs, is unaffected by glucose levels, and offers an advantage over 18F-FDG. It has been used in a variety of solid tumors ranging from hepatobiliary tumors, carcinoma breast, gynecological malignancies, and sarcoma [7,10]. Many radiolabeled fibroblast activation protein inhibitor tracers are being investigated as PET radiotracer agents and for possible use in theranostic applications [11].

## Case Presentation

We report a case of biopsy-proven pancreatic adenocarcinoma with liver metastases. The index case is a 61-year-old lady presenting with complaints of nausea, vomiting, and abdominal pain for three months.

### How to cite this article

Kumar A, Kumar B, Kumar Upadhyay A, et al. (December 08, 2023) Gallium68-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT as an Alternative to Fluoro18-Fluorodeoxyglucose (18F-FDG) PET/CT: Discussion in a Case of Metastatic Adenocarcinoma of Pancreas. Cureus 15(12): e50183. DOI 10.7759/cureus.50183


Ultrasound of the abdomen revealed hepatomegaly with multiple liver lesions suggestive of liver secondaries. Biopsy from the liver lesion suggested metastatic adenocarcinoma. The patient was scheduled for FDG PET/CT for evaluation of these liver lesions and identification of the primary neoplastic site. However, due to uncontrolled diabetes and a fasting blood glucose level of 270 mg/dL, FDG PET/CT was deferred. In consultation with a medical oncologist, 68Ga-FAPI PET/CT was done. Subsequently, after two days, when fasting blood glucose level was under control, 18F-FDG PET/CT was also done to confirm the findings. Both the PET/CT scans were done after obtaining written consent from the patient. The maximum standardized uptake values (SUVmax) were compared for both scans.

68Ga-FAPI PET/CT revealed enhancing primary neoplastic lesion in the head and uncinate process of the pancreas with radiotracer uptake (SUVmax 17.3). Multiple FAPI avid (SUVmax 9.6) liver lesions were also seen, suggesting liver metastases. FAPI avid nodal metastases were noted in portocaval (SUVmax 14.8) and anterior cardiac recess (SUVmax 5.3) regions. FAPI avid deposit (SUVmax 6.0) was also noted in the perinephric region of the right kidney. Background SUVmax of 3.5 was noted on FAPI PET.

18F-FDG PET/CT revealed similar findings in primary and metastatic sites with a primary neoplastic lesion involving the pancreas (SUVmax 7.5) and multiple metastatic liver lesions (SUVmax 6.4). FDG avid nodal metastases in portocaval (SUVmax 5.1) and anterior cardiac recess (SUVmax 1.4) regions with another deposit (SUVmax 2.6) in the perinephric region of the right kidney were noted. These lymph nodes and perinephric deposits were deemed metastatic by two nuclear medicine physicians in view of contrast enhancement and higher uptake values on FAPI PET. Background SUVmax of 2.7 was noted on FDG PET.

On comparison of both these scans, it was noted that both these radiotracers identified the primary and metastatic sites. However, FAPI uptake was higher in primary and metastatic sites, resulting in a better tumor-to-background ratio. Also, FAPI uptake was seen in more number of the liver lesions as compared to FDG, thus identifying a higher burden of tumor volume.


Diagnosis of stage IV pancreatic cancer with liver metastases was established in conjunction with these imaging findings. The patient was explained the stage of the disease and the associated poor prognosis. Subsequently, she was started on palliative chemotherapy with a Gemcitabine and Paclitaxel-based regimen and awaits follow-up (Figures 1A-1E, 2A-2E).



**FIGURE 1: 68Ga-FAPI PET/CT images of the patient**

(A) MIP; (B, D) axial view of CT; (C, E) axial view of 68Ga-FAPI PET/CT fusion. MIP image shows increased FAPI uptake in the region of the pancreas (white arrow) and metastatic liver lesions (red arrows). (B, C) Primary neoplastic lesion involving head and uncinate process of pancreas with FAPI uptake (white arrows). (D, E) Metastatic liver lesions with FAPI uptake (white arrows).

MIP: maximal intensity projection; 68Ga-FAPI PET/CT: 68Ga-fibroblast activation protein inhibitor positron emission tomography/computed tomography; FAPI: fibroblast activation protein inhibitor.



**FIGURE 2: 18F-FDG PET/CT images of the patient**

(A) MIP; (B, D) axial view of CT; (C, E) axial view of 18F-FDG PET/CT fusion. MIP image shows increased FDG uptake in the region of the pancreas (white arrows) and metastatic liver lesions (red arrows). (B, C) Primary neoplastic lesion involving head and uncinate process of pancreas with FDG uptake (white arrows). (D, E) Metastatic liver lesions with FDG uptake (white arrows).

MIP: maximal intensity projection; 18F-FDG PET/CT: 18F-fluorodeoxyglucose positron emission tomography/computed tomography; FDG: fluorodeoxyglucose.

## Discussion

PET/CT is an invaluable tool for staging and response evaluation of most malignant solid tumors in present-day oncology. Many PET agents have been developed and used over time, and 18F-FDG is the most commonly used PET radiotracer worldwide. It has been used extensively over the past few decades and is the agent of choice for imaging of solid tumors like carcinoma lung, breast, lymphomas, etc. However, despite being a standard modality, it is still not a malignancy-specific agent. FDG uptake can be seen in infective and inflammatory conditions [6]. It is also seen as post-treatment inflammatory changes in tumors, at certain times posing a challenge in response evaluation to identify viable residual neoplastic disease. Another limitation is its dependency on blood glucose levels in patients and possible interference with antidiabetic medications and insulin. There has been extensive research in developing malignancy-specific PET agents over time. The development of PET agents like DOTANOC and PSMA is a result of these research initiatives. Radioisotope-labeled FAP inhibitors are today one of the promising PET agents undergoing extensive research. It targets the cancer-associated fibroblasts in tumors and might be an alternative to FDG. Also, it offers the advantage of not being dependent on blood glucose levels in patients. 68Ga-FAPI being produced at the site itself also provides flexibility in performing the PET CT as required and is not dependent on the supply of radiotracer from the cyclotron facility.

In our case study, PET agent FAPI identified the primary disease involving the pancreas with nodal and liver metastases. Compared to FDG PET, the SUVmax values were higher. Also, FAPI was positive in more number of liver lesions and hence more sensitive in identifying the bulk of the disease. Many research publications have emphasized the utility of PET agent FAPI in the detection and staging of various malignancies. Lan et al. compared 68Ga-FAPI and 18F-FDG PET/CT for staging of biliary tract tumors [12]. They reported a higher sensitivity of 68Ga-FAPI PET/CT in detecting primary tumors. 68Ga-FAPI PET/CT resulted in new oncologic findings and upgraded tumor staging or restaging in a subset of patients. In another study, Wang et al. compared 68Ga-FAPI and 18F-FDG PET/CT in the evaluation of advanced lung cancer [13]. In this study, 68Ga-FAPI, in comparison to 18F-FDG, depicted more suspected metastases in lymph nodes, brain, bone, and pleura. Similarly, Liu et al. demonstrated a higher sensitivity of 68 Ga-FAPI PET/CT than 18 F-FDG PET/CT in detecting tumor recurrence, nodal metastases, and distant metastases in gastrointestinal malignancies [14]. As per these studies, PET agent FAPI may be a substitute for 18F-FDG with possible theranostic applications in the future [11, 15]. However, FAPI PET is not completely specific for malignancy. FAPI uptake has been reported in infectious and chronic inflammatory conditions [16]. More data is required to validate the use of FAPI in staging and response evaluation of various malignancies.

## Conclusions

The results of this case discussion demonstrate that PET agent FAPI with selective tumor uptake has the potential for use in the staging and evaluation of malignancies. It not only contributes to the assessment of the burden of metastatic disease but also guides clinical decision-making for relevant therapy. It could

potentially be an alternative to FDG PET/CT in uncontrolled diabetic patients, which is a common co-morbidity in cancer patients.

## Additional Information

### Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

**Concept and design:** Abhishek Kumar, Bhola Kumar, Amitabh Kumar Upadhyay, G. S. Muthu, Sujata Mitra

**Acquisition, analysis, or interpretation of data:** Abhishek Kumar, Bhola Kumar, G. S. Muthu, Sujata Mitra

**Drafting of the manuscript:** Abhishek Kumar, Bhola Kumar, Amitabh Kumar Upadhyay, G. S. Muthu, Sujata Mitra

**Critical review of the manuscript for important intellectual content:** Abhishek Kumar, Amitabh Kumar Upadhyay, G. S. Muthu, Sujata Mitra

**Supervision:** Abhishek Kumar, Bhola Kumar, Amitabh Kumar Upadhyay, G. S. Muthu, Sujata Mitra

### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

## References

- Hirata K, Kamagata K, Ueda D, et al.: From FDG and beyond: the evolving potential of nuclear medicine . *Ann Nucl Med*. 2023, 37:583-95. [10.1007/s12149-023-01865-6](https://doi.org/10.1007/s12149-023-01865-6)
- Fortunati E, Bonazzi N, Zannoni L, Fanti S, Ambrosini V: Molecular imaging theranostics of neuroendocrine tumors. *Semin Nucl Med*. 2023, 53:539-54. [10.1053/j.semnuclmed.2022.12.007](https://doi.org/10.1053/j.semnuclmed.2022.12.007)
- Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, Bal C: Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. *AJR Am J Roentgenol*. 2011, 197:1221-8. [10.2214/AJR.11.7298](https://doi.org/10.2214/AJR.11.7298)
- von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G: (68)ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. *Eur Urol Focus*. 2018, 4:686-93. [10.1016/j.euf.2016.11.002](https://doi.org/10.1016/j.euf.2016.11.002)
- Mena E, Lindenberg L, Choyke P: The impact of PSMA PET/CT imaging in prostate cancer radiation treatment. *Semin Nucl Med*. 2022, 52:255-62. [10.1053/j.semnuclmed.2021.12.008](https://doi.org/10.1053/j.semnuclmed.2021.12.008)
- Pijl JP, Glaudemans AW, Gheysens O, Slart RH, Kwee TC: Importance of blood glucose management before (18)f-FDG PET/CT in 322 patients with bacteremia of unknown origin. *J Nucl Med*. 2023, 64:1287-94. [10.2967/jnumed.122.264839](https://doi.org/10.2967/jnumed.122.264839)
- Chandekar KR, Prashanth A, Vinjamuri S, Kumar R: FAPI PET/CT imaging-an updated review. *Diagnostics (Basel)*. 2023, 13:2018. [10.3390/diagnostics13122018](https://doi.org/10.3390/diagnostics13122018)
- Parihar AS, Dehdashti F, Wahl RL: FDG PET/CT-based response assessment in malignancies . *Radiographics*. 2023, 43:e220122. [10.1148/rq.220122](https://doi.org/10.1148/rq.220122)
- Gomes Marin JF, Nunes RF, Coutinho AM, et al.: Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. *Radiographics*. 2020, 40:1715-40. [10.1148/rq.2020200021](https://doi.org/10.1148/rq.2020200021)
- Kratochwil C, Flechsig P, Lindner T, et al.: (68)ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer . *J Nucl Med*. 2019, 60:801-5. [10.2967/jnumed.119.227967](https://doi.org/10.2967/jnumed.119.227967)
- Liu Y, Watabe T, Kaneda-Nakashima K, et al.: Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model. *Eur J Nucl Med Mol Imaging*. 2022, 49:871-80. [10.1007/s00259-021-05554-2](https://doi.org/10.1007/s00259-021-05554-2)
- Lan L, Zhang S, Xu T, et al.: Prospective comparison of (68)ga-FAPI versus (18)f-FDG PET/CT for tumor staging in biliary tract cancers. *Radiology*. 2022, 304:648-57. [10.1148/radiol.213118](https://doi.org/10.1148/radiol.213118)
- Wang L, Tang G, Hu K, et al.: Comparison of (68)ga-FAPI and (18)f-FDG PET/CT in the evaluation of advanced lung cancer. *Radiology*. 2022, 303:191-9. [10.1148/radiol.211424](https://doi.org/10.1148/radiol.211424)
- Liu H, Yang X, Liu L, Qu G, Chen Y: Comparison of 18 F-FDG and 68 Ga-FAPI-04 uptake in postoperative re-evaluation of gastric, duodenal, and colorectal cancers. *Clin Nucl Med*. 2023, 48:304-8. [10.1097/RLU.0000000000004604](https://doi.org/10.1097/RLU.0000000000004604)
- Zhao L, Chen J, Pang Y, et al.: Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. *Theranostics*. 2022, 12:1557-69. [10.7150/thno.69475](https://doi.org/10.7150/thno.69475)
- Bentestuen M, Al-Obaydi N, Zacho HD: FAPI-avid nonmalignant PET/CT findings: an expedited systematic

